SCHEMBL4615036

SCHEMBL4615036

CCCCCNc1ncc(Br)s1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPK10 P53779 1/20 0.55
SMN1; SMN2 Q16637 1/20 0.55
MMP3 P08254 1/20 0.44
LIMK1 P53667 2/20 0.42
NPC1 O15118 2/20 0.40
ALDH1A1 P00352 1/20 0.40
MAPT P10636 1/20 0.40
STAT1 P42224 1/20 0.40
RAB9A P51151 1/20 0.40
KDR P35968 1/20 0.38
HCAR3 P49019 1/20 0.38
CCNE1 P24864 1/20 0.37
CDK2 P24941 1/20 0.37
CDK5 Q00535 1/20 0.37
ABL1 P00519 1/20 0.36
FPR3 P25089 1/20 0.36
FPR2 P25090 1/20 0.36
ALPL P05186 1/20 0.36
ALPI P09923 1/20 0.36
DNM2 P50570 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12963498 0.87 LIMK1 (0.53) MAPK10SMN1; SMN2LIMK1KDRCCNE1
SCHEMBL8348553 0.80
SCHEMBL5492777 0.74 MMP3 (0.40) MMP3LIMK1NPC1ALDH1A1MAPT
SCHEMBL936007 0.74 LIMK1 (0.48) MMP3LIMK1NPC1ALDH1A1MAPT
SCHEMBL16208277 0.73 LMNA (0.61) SMN1; SMN2NPC1ALDH1A1MAPTRAB9A
SCHEMBL19439115 0.73 MMP3 (0.39) SMN1; SMN2MMP3LIMK1NPC1ALDH1A1
SCHEMBL8351433 0.72
SCHEMBL12933432 0.71 SMN1; SMN2 (0.43) MAPK10SMN1; SMN2NPC1RAB9AKDR
SCHEMBL28009559 0.68 CYP1A2 (0.40) SMN1; SMN2MMP3LIMK1NPC1ALDH1A1
SCHEMBL15341105 0.68 KDR (0.43) MAPK10SMN1; SMN2LIMK1NPC1RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-101273023-A 5-substituted thiazol-2-ylamino compounds and compositions as protein kinase inhibitors IRM LLC (BM) 2008-09-24 CN disclosed
US-20080227783-A1 5-Substituted Thiazol-2-Yl Amino Compounds and Compositions as Protein Kinase Inhibitors IRM LLC (BM) 2008-09-18 US disclosed
EP-1912959-A2 5-SUBSTITUTED THIAZOL-2-YL AMINO COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2008-04-23 EP disclosed
WO-2007016228-A2 5-SUBSTITUTED THIAZOL-2-YL AMINO COMPOUNDS AND COMPOSITIONS AS PROTEIN KINASE INHIBITORS IRM LLC (BM) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080227783-A1 5-Substituted Thiazol-2-Yl Amino Compounds and Compositions as Protein Kinase Inhibitors BMX, CDK1, CKS1B MAPK10 148/4885SMN1; SMN2 1919/4885MMP3 4189/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.